Loading...

Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination

A Bayesian design is presented that does precision dose-finding based on time to toxicity in a phase I clinical trial with two or more patient subgroups. The design, called Sub-TITE, makes sequentially adaptive subgroup-specific decisions while possibly combining subgroups that have similar estimate...

Full description

Saved in:
Bibliographic Details
Published in:Pharm Stat
Main Authors: Chapple, Andrew G., Thall, Peter F.
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6640643/
https://ncbi.nlm.nih.gov/pubmed/30112806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pst.1891
Tags: Add Tag
No Tags, Be the first to tag this record!